Who Paid My Doc
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Research payments
$372,779
Through program year 2021, $372,779 in research payments was reported against A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension, across 170 payments, paid by United Therapeutics Corporation.
- Paid by
- United Therapeutics Corporation
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $41,880 | 22 |
| 2020 | Research | $330,899 | 148 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- David Badesch Aurora, CO Named on 12 payments
- Daniel Layish Orlando, FL Named on 12 payments
- Stacy Fisher Baltimore, MD Named on 9 payments
- Evelyn Horn New York, NY Named on 7 payments
- Austin Thompson Omaha, NE Named on 7 payments
- Roger Alvarez Miami, FL Named on 7 payments
- Jason Fritz Philadelphia, PA Named on 7 payments
- Elizabeth Klings Boston, MA Named on 6 payments
- Roblee Allen Sacramento, CA Named on 6 payments
- Paresh Giri South Pasadena, CA Named on 6 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.